Viewing nowCombinationSitagliptin Plus Tablet 50/850 mg (Sitagliptin, Metformin)
Sitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Hana Pharmaceutical Co., Ltd.

MFDS item code 202204585 · Approved 2022.12.21 · Insurance code 657807980
Improvement of glycemic control in patients with type 2 diabetes mellitus
This medication helps control blood sugar in patients with type 2 diabetes together with dietary control and exercise therapy. It assists in effective management of blood sugar by using sitagliptin and metformin together. Thus, it is used for the treatment of type 2 diabetes.
The dose of this medication for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medication is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. The initial dose of this medication should be determined according to the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients who have not previously received antidiabetic drug therapy and whose blood glucose is not adequately controlled with monotherapy, or for patients whose blood glucose is not adequately controlled with sitagliptin monotherapy, the initial dose is 1 tablet of this medication 50/500 mg twice daily. The dose may be increased to 1 tablet of this medication 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medication (see Precautions for Use, 2. Patients Who Must Not Receive This Medication). 2. Patients receiving metformin: - For patients whose blood glucose is not adequately controlled with metformin monotherapy, the recommended initial dose of this medication is sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient's current metformin dose. - Patients switching from concomitant sitagliptin and metformin therapy to this medication may start at their current doses of sitagliptin and metformin. 3. Patients whose blood glucose is not adequately controlled with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medication is sitagliptin 50 mg twice daily (total daily dose 100 mg). The initial dose of metformin should be determined based on the patient's blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When administered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia caused by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). No studies have been conducted to assess the safety and efficacy of switching patients previously treated with other oral antihyperglycemic agents to this medication. Any change in the treatment regimen for type 2 diabetes may affect blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medication may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this medication because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be carefully monitored every 3-6 months. If renal function decreases to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medication should be discontinued immediately. Patients with hepatic impairment This medication should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients Who Must Not Receive This Medication).
This medication contains two ingredients, sitagliptin and metformin. First, sitagliptin can cause a rare but severe allergic reaction, so if symptoms such as skin rash, difficulty breathing, or swelling of the face or neck occur within 3 months of administration, the medication should be discontinued immediately and a doctor should be consulted. Moreover, sitagliptin can cause a serious side effect known as acute pancreatitis, which is inflammation of the pancreas. If symptoms such as abdominal pain, nausea, vomiting, or loss of appetite occur, notify healthcare personnel promptly. Metformin can cause a rare but fatal metabolic disorder called lactic acidosis, and this medication should not be taken if there is impaired kidney function, liver disease, dehydration, or severe infection. Also, if there is sudden dehydration, severe diarrhea, or vomiting, the medication should be stopped and a doctor consulted. This medication should not be administered to patients with moderate to severe renal impairment, and regular kidney function tests should be conducted. Special caution is necessary for elderly patients or those with weakened kidney function. Alcohol consumption should be avoided while taking this medication, and the medication should be temporarily stopped around the time of sudden surgery or radiologic investigations involving contrast agents. Additionally, because there is a risk of hypoglycemia, meals should be eaten regularly, and when taken together with other hypoglycemic agents or insulin, care should be taken for signs of hypoglycemia. Symptoms of hypoglycemia may include dizziness, cold sweat, tremor, and fatigue, and if they occur, take sugar immediately and consult healthcare personnel. This medication is not to be administered to pregnant women or women who may become pregnant, as well as to nursing mothers. Finally, any unusual skin rashes, severe joint pain, or blisters around the mouth while taking this medication should be reported to a doctor immediately. During the course of this medication, it is important to regularly check blood sugar levels, kidney function, liver function, and vitamin B12 levels and consult healthcare personnel quickly if any discomfort occurs.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to keep out air and moisture, and the storage temperature should be maintained between 1 degrees Celsius and 30 degrees Celsius. By storing it this way, the effectiveness of the medication can be maintained for a longer period.
Oval film-coated tablet in dark pink color
56 tablets/box [(14 tablets/PTP x 4)], 30 tablets/bottle, 200 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Hana Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Korea Hutech Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.